| 前收盘价格 | 13.28 |
| 收盘价格 | 13.28 |
| 成交量 | 527,000 |
| 平均成交量 (3个月) | 1,669,320 |
| 市值 | 13,588,617,216 |
| 价格/销量 (P/S) | 4.70 |
| 股市价格/股市净资产 (P/B) | 2.74 |
| 52周波幅 | |
| 利润日期 | 25 Mar 2025 - 31 Mar 2025 |
| 营业毛利率 | -101.95% |
| 营业利益率 (TTM) | -59.84% |
| 稀释每股收益 (EPS TTM) | -3.17 |
| 季度收入增长率 (YOY) | 34.60% |
| 总债务/股东权益 (D/E MRQ) | 106.93% |
| 流动比率 (MRQ) | 1.36 |
| 营业现金流 (OCF TTM) | -1.22 B |
| 杠杆自由现金流 (LFCF TTM) | -1.17 B |
| 资产报酬率 (ROA TTM) | -17.33% |
| 股东权益报酬率 (ROE TTM) | -49.08% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | REMEGEN | - | - |
AIStockmoo 评分
-1.6
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -1.63 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| REMEGEN | 14 B | - | - | 2.74 |
| ASYMCHEM | 29 B | 3.60% | 21.01 | 1.02 |
| JUNSHI BIO | 24 B | - | - | 1.56 |
| ZAI LAB | 23 B | - | - | 4.38 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 13.20% |
| 机构持股比例 | 37.18% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合